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distribution was calculated with the isocenter placed at the 
actual isocenter, ie. corrected for the set-up error. The 
Cumulated Dose Distribution (CDDall) was calculated as the 
sum of all dose distributions for each single fraction. Next we 
calculated the Mean Dose Distribution MDDN obtained for 
mean setup error of N = 2, 3, …,15, 20 and 25 first fractions. 
All dose distributions were saved in the DICOM RT Dose 
format and exported to Verisoft (PTW). The Verisoft software 
was used for comparison of the MDDN with CDDall. The gamma 
concept with 2mm and 2% of max dose was used for 
comparison of each pair of dose distributions. 
Results: For 3D technique for all pairs of dose distributions 
the gamma index was always smaller than 1 in at least 75.9% 
of voxels. For mean dose distributions calculated from at 
least 7 first fractions (MDDN>6) for all patients, but one the 
gamma index was smaller than 1 for at least 95% of voxels. 
For IMRT technique the gamma index was always smaller than 
1 in at least 81.3% of voxels. For this technique for the MDD 
calculated from at least 8 first fractions (MDDN>7) for all 
patients the gamma index was smaller than 1 in at least 95% 
of voxels. For VMAT technique the gamma index was always 
smaller than 1 in at least 86.1% of voxels. For this technique 
the MDD calculated from at least 3 first fractions (MDDN>2) for 
all patients the gamma index was > 1 in at least 95% of 
points. Results are presented in Figure 1. 
 
Figure 1. Results of Gamma index based comparison of 3D 
dose distributions for 25 patients. 
 
Conclusions: The cumulated dose distribution CDDall can be 
estimated with the dose distribution calculated as a mean 
dose distribution calculated with at least 8 fractions 
regardless of the technique. For VMAT technique the CDDall 
may be estimated with 3 first fractions only. 
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Purpose/Objective: To evaluate the accuracy of a stereo 
ToF-system for patient positioning in radiotherapy. 
Materials and Methods: We retrospectively analyzed data 
from 150 fractions of thorax, pelvic-prostate, and head and 
neck cancer treatments (50 for each location). First, the 
patient was placed thanks to a system of lasers and tattoo 
points. Then kV images were acquired to improve the 
positioning using bone structures registration. The applied 
table shifts were recorded. Using two ToF cameras mounted 
on the ceiling of the radiotherapy treatment room, two ToF 
images at a same breathing phase were recorded: one before 
and one after the table shift. These two images were then 
rigidly registered and the obtained displacements were 
compared to the image based displacement. 
Results: We obtained mean absolute errors of 0.8 ± 0.7 mm 
for all localities along the vertical and longitudinal axes, and 
0.7 ± 0.6 mm along the lateral axis. Our results showed an 
improvement compared to the two commercialized systems 
that use the patient surface for positioning: the Sentinel form 
C-RAD and the AlignRT from VisonRT. The obtained errors are 




This table indicated a full norm displacement of 0.8 ± 0.7 mm 
in comparison to 2.16 ± 1.5 mm in the case of the AlignRT. 
Similarly, for pelvic regions, our system showed better results 
(0.7 ± 0.6 mm, 0.7 ± 0.6 mm, and 0.6 ± 0.4 mm for the 
vertical, longitudinal, and lateral axes respectively) in 
comparison to the Sentinel system (2.9 ± 2.0 mm, 3.4 ± 2.2 
mm, and 2.5 ± 2.3 mm along the same three axes). 
Conclusions: Our ToF-system ensures a sufficient accuracy 
for patient positioning in radiotherapy. The next step will be 
to integrate a patient-specific model in order to link the 
patient surface deformations to the internal deformations 
and enhance the accuracy of tumor and organs at risk 
positioning. 
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Purpose/Objective: The purpose of this study was to develop 
a method to use adaptive planning on Tomotherapy with 
deformable registration. The existing method is a new CT 
scan when large variations in patient anatomy, e. g. tumour 
shrinkage, are introduced during treatment. When a new CT 
scan is made on patient undergoing treatment, redelineation 
of structures, reoptimisation and QA measurements are 
S824                                                                                                                                         3rd ESTRO Forum 2015 
 
necessary. It is a time consuming task and during this time 
the patient are treated with a suboptimal planor put on hold. 
Instead, a deformable registration can be made in an 
external software using MVCT scans from the Tomotherapy 
treatment as base to deform the original CT to be similar to 
the patients present anatomy. The structures are deformed 
with the CT and a new optimisation and QA can be made, the 
whole process can be ready until the next treatment. This 
deformed CT with plan can be used waiting for the new CT 
scan or replace it altogether.  
Materials and Methods: The first step was to verify the 
deformable registration. We used a third party software 
called InSimQA to deform a CT with structures which in turn 
was exported to our deformable registration software in 
Varian Eclipse to be deformed back. The difference in 
structure deformation was evaluated with Dice similarity 
index and volume difference. A Tomotherapy plan was also 
optimized on the CT deformed in InSimQA and the CT 
deformed back in Eclipse. The difference between the CT in 
Eclipse and the original CT, and CT from InSimQA against the 
original CT respectively, was evaluated. We used gamma 
index to compare the dose distributions. 
In the second step we used a patient previously treated with 
Tomotherapy, rescanned and reoptimised. The original CT 
was deformed with a MVCT as base. As a reference the 
original CT was deformed with the rescanned CT as base to 
compare delineation of structures between the rescanned CT 
and the original CT. A Tomotherapy plan was also optimised 
on the deformed CT and one on the rescanned CT and 
compared. We compared the plan optimised from the 
deformed CT but recalculated on the rescanned CT against 
the rescanned CT plan. We used gamma index to compare 
the dose distributions.  
 
 
Results: The result of our analysis is presented in table 1. For 
the Retrospective patient analysis we see a good agreement 
between target structures but not on parotis. That difference 
could be due to delineation differences since the agreement 
even to CT to CT deformation is Dice index of 0.75. Gamma 
analysis on dose show a good pass with 96.25% pass rate on 
the total body. 
Conclusions: The method is possible to use as a method for 
adaptive planning on Tomotherapy, even if further analysis is 
required. It is essential that a complete verification process 
for the deformable registration is in place. A recalculation of 
the new plan on an existing MVCT to verify dose distribution 
and important risk organs as medulla spinalis is prudent.  
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